Skip to main content
Top
Published in: Breast Cancer Research 2/2011

Open Access 01-04-2011 | Research article

Genetic variation in PRL and PRLR, and relationships with serum prolactin levels and breast cancer risk: results from a population-based case-control study in Poland

Authors: Sarah J Nyante, Jessica M Faupel-Badger, Mark E Sherman, Ruth M Pfeiffer, Mia M Gaudet, Roni T Falk, Abegail A Andaya, Jolanta Lissowska, Louise A Brinton, Beata Peplonska, Barbara K Vonderhaar, Stephen Chanock, Montserrat Garcia-Closas, Jonine D Figueroa

Published in: Breast Cancer Research | Issue 2/2011

Login to get access

Abstract

Introduction

Studies suggest that high circulating levels of prolactin increase breast cancer risk. It is unclear if genetic variations in prolactin (PRL) or prolactin receptor (PRLR) genes also play a role. Thus, we examined the relationship between single nucleotide polymorphisms (SNPs) in PRL and PRLR, serum prolactin levels and breast cancer risk in a population-based case-control study.

Methods

We genotyped 8 PRL and 20 PRLR tag SNPs in 1965 breast cancer cases and 2229 matched controls, aged 20-74, and living in Warsaw or Łódź, Poland. Serum prolactin levels were measured by immunoassay in a subset of 773 controls. Odds ratios (ORs) and 95% confidence intervals (CIs) for genotype associations with breast cancer risk were estimated using unconditional logistic regression, adjusted for age and study site. Geometric mean prolactin levels were estimated using linear regression models adjusted for age, study site, blood collection time, and menstrual cycle day (premenopausal women).

Results

Three SNPs were associated with breast cancer risk: in premenopausal women, PRLR rs249537 (T vs. C per-allele OR 1.39, 95% CI 1.07 - 1.80, P = 0.01); and in postmenopausal women, PRLR rs7718468 (C vs. T per-allele OR 1.16, 95% CI 1.03 - 1.30, P = 0.01) and PRLR rs13436213 (A vs. G per-allele OR 1.13 95% CI 1.01 - 1.26, P = 0.04). However, mean serum prolactin levels for these SNPs did not vary by genotype (P-trend > 0.05). Other SNPs were associated with serum prolactin levels: PRLR rs62355518 (P-trend = 0.01), PRLR rs10941235 (P-trend = 0.01), PRLR rs1610218 (P-trend = 0.01), PRLR rs34024951 (P-trend = 0.02), and PRLR rs9292575 (P-trend = 0.03) in premenopausal controls and PRL rs849872 (P-trend = 0.01) in postmenopausal controls.

Conclusions

Our data provide limited support for an association between common variations in PRLR and breast cancer risk. Altered serum prolactin levels were not associated with breast cancer risk-associated variants, suggesting that common genetic variation is not a strong predictor of prolactin-associated breast cancer risk in this population.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bachelot A, Binart N: Reproductive role of prolactin. Reproduction. 2007, 133: 361-369. 10.1530/REP-06-0299.CrossRef Bachelot A, Binart N: Reproductive role of prolactin. Reproduction. 2007, 133: 361-369. 10.1530/REP-06-0299.CrossRef
2.
go back to reference Clevenger CV, Furth PA, Hankinson SE, Schuler LA: The role of prolactin in mammary carcinoma. Endocr Rev. 2003, 24: 1-27. 10.1210/er.2001-0036.CrossRef Clevenger CV, Furth PA, Hankinson SE, Schuler LA: The role of prolactin in mammary carcinoma. Endocr Rev. 2003, 24: 1-27. 10.1210/er.2001-0036.CrossRef
3.
go back to reference Touraine P, Martini JF, Zafrani B, Durand JC, Labaille F, Malet C, Nicolas A, Trivin C, Postel-Vinay MC, Kuttenn F, Kelly PA: Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J Clin Endocrinol Metab. 1998, 83: 667-674. 10.1210/jc.83.2.667.CrossRef Touraine P, Martini JF, Zafrani B, Durand JC, Labaille F, Malet C, Nicolas A, Trivin C, Postel-Vinay MC, Kuttenn F, Kelly PA: Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J Clin Endocrinol Metab. 1998, 83: 667-674. 10.1210/jc.83.2.667.CrossRef
4.
go back to reference Clevenger CV, Chang WP, Ngo W, Pasha TL, Montone KT, Tomaszewski JE: Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. Am J Pathol. 1995, 146: 695-705.PubMedPubMedCentral Clevenger CV, Chang WP, Ngo W, Pasha TL, Montone KT, Tomaszewski JE: Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. Am J Pathol. 1995, 146: 695-705.PubMedPubMedCentral
5.
go back to reference Gill S, Peston D, Vonderhaar BK, Shousha S: Expression of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study. J Clin Pathol. 2001, 54: 956-960. 10.1136/jcp.54.12.956.CrossRef Gill S, Peston D, Vonderhaar BK, Shousha S: Expression of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study. J Clin Pathol. 2001, 54: 956-960. 10.1136/jcp.54.12.956.CrossRef
6.
go back to reference Ginsburg E, Vonderhaar BK: Prolactin synthesis and secretion by human breast cancer cells. Cancer Res. 1995, 55: 2591-2595.PubMed Ginsburg E, Vonderhaar BK: Prolactin synthesis and secretion by human breast cancer cells. Cancer Res. 1995, 55: 2591-2595.PubMed
7.
go back to reference Perks CM, Keith AJ, Goodhew KL, Savage PB, Winters ZE, Holly JM: Prolactin acts as a potent survival factor for human breast cancer cell lines. Br J Cancer. 2004, 91: 305-311.CrossRef Perks CM, Keith AJ, Goodhew KL, Savage PB, Winters ZE, Holly JM: Prolactin acts as a potent survival factor for human breast cancer cell lines. Br J Cancer. 2004, 91: 305-311.CrossRef
8.
go back to reference Vonderhaar BK: Prolactin involvement in breast cancer. Endocr Relat Cancer. 1999, 6: 389-404. 10.1677/erc.0.0060389.CrossRef Vonderhaar BK: Prolactin involvement in breast cancer. Endocr Relat Cancer. 1999, 6: 389-404. 10.1677/erc.0.0060389.CrossRef
9.
go back to reference Helzlsouer KJ, Alberg AJ, Bush TL, Longcope C, Gordon GB, Comstock GW: A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev. 1994, 18: 79-85.PubMed Helzlsouer KJ, Alberg AJ, Bush TL, Longcope C, Gordon GB, Comstock GW: A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev. 1994, 18: 79-85.PubMed
10.
go back to reference Manjer J, Johansson R, Berglund G, Janzon L, Kaaks R, Agren A, Lenner P: Postmenopausal breast cancer risk in relation to sex steroid hormones, prolactin and SHBG (Sweden). Cancer Causes Control. 2003, 14: 599-607. 10.1023/A:1025671317220.CrossRef Manjer J, Johansson R, Berglund G, Janzon L, Kaaks R, Agren A, Lenner P: Postmenopausal breast cancer risk in relation to sex steroid hormones, prolactin and SHBG (Sweden). Cancer Causes Control. 2003, 14: 599-607. 10.1023/A:1025671317220.CrossRef
11.
go back to reference Tworoger SS, Eliassen AH, Sluss P, Hankinson SE: A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol. 2007, 25: 1482-1488. 10.1200/JCO.2006.07.6356.CrossRef Tworoger SS, Eliassen AH, Sluss P, Hankinson SE: A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol. 2007, 25: 1482-1488. 10.1200/JCO.2006.07.6356.CrossRef
12.
go back to reference Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE: A prospective study of estradiol and breast cancer in Japanese women. Cancer Epidemiol Biomarkers Prev. 2000, 9: 575-579.PubMed Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE: A prospective study of estradiol and breast cancer in Japanese women. Cancer Epidemiol Biomarkers Prev. 2000, 9: 575-579.PubMed
13.
go back to reference Wang DY, De Stavola BL, Bulbrook RD, Allen DS, Kwa HG, Fentiman IS, Hayward JL, Millis RR: Relationship of blood prolactin levels and the risk of subsequent breast cancer. Int J Epidemiol. 1992, 21: 214-221. 10.1093/ije/21.2.214.CrossRef Wang DY, De Stavola BL, Bulbrook RD, Allen DS, Kwa HG, Fentiman IS, Hayward JL, Millis RR: Relationship of blood prolactin levels and the risk of subsequent breast cancer. Int J Epidemiol. 1992, 21: 214-221. 10.1093/ije/21.2.214.CrossRef
14.
go back to reference Tworoger SS, Hankinson SE: Prolactin and breast cancer etiology: an epidemiologic perspective. J Mammary Gland Biol Neoplasia. 2008, 13: 41-53. 10.1007/s10911-008-9063-y.CrossRef Tworoger SS, Hankinson SE: Prolactin and breast cancer etiology: an epidemiologic perspective. J Mammary Gland Biol Neoplasia. 2008, 13: 41-53. 10.1007/s10911-008-9063-y.CrossRef
15.
go back to reference Faupel-Badger JM, Sherman ME, Garcia-Closas M, Gaudet MM, Falk RT, Andaya A, Pfeiffer RM, Yang XR, Lissowska J, Brinton LA, Peplonska B, Vonderhaar BK, Figueroa JD: Prolactin serum levels and breast cancer: relationships with risk factors and tumour characteristics among pre- and postmenopausal women in a population-based case-control study from Poland. Br J Cancer. 2010, 103: 1097-1102. 10.1038/sj.bjc.6605844.CrossRef Faupel-Badger JM, Sherman ME, Garcia-Closas M, Gaudet MM, Falk RT, Andaya A, Pfeiffer RM, Yang XR, Lissowska J, Brinton LA, Peplonska B, Vonderhaar BK, Figueroa JD: Prolactin serum levels and breast cancer: relationships with risk factors and tumour characteristics among pre- and postmenopausal women in a population-based case-control study from Poland. Br J Cancer. 2010, 103: 1097-1102. 10.1038/sj.bjc.6605844.CrossRef
16.
go back to reference Stevens A, Ray D, Alansari A, Hajeer A, Thomson W, Donn R, Ollier WE, Worthington J, Davis JR: Characterization of a prolactin gene polymorphism and its associations with systemic lupus erythematosus. Arthritis Rheum. 2001, 44: 2358-2366. 10.1002/1529-0131(200110)44:10<2358::AID-ART399>3.0.CO;2-K.CrossRef Stevens A, Ray D, Alansari A, Hajeer A, Thomson W, Donn R, Ollier WE, Worthington J, Davis JR: Characterization of a prolactin gene polymorphism and its associations with systemic lupus erythematosus. Arthritis Rheum. 2001, 44: 2358-2366. 10.1002/1529-0131(200110)44:10<2358::AID-ART399>3.0.CO;2-K.CrossRef
17.
go back to reference Bogorad RL, Courtillot C, Mestayer C, Bernichtein S, Harutyunyan L, Jomain JB, Bachelot A, Kuttenn F, Kelly PA, Goffin V, Touraine P: Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors. Proc Natl Acad Sci USA. 2008, 105: 14533-14538. 10.1073/pnas.0800685105.CrossRef Bogorad RL, Courtillot C, Mestayer C, Bernichtein S, Harutyunyan L, Jomain JB, Bachelot A, Kuttenn F, Kelly PA, Goffin V, Touraine P: Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors. Proc Natl Acad Sci USA. 2008, 105: 14533-14538. 10.1073/pnas.0800685105.CrossRef
18.
go back to reference Courtillot C, Chakhtoura Z, Bogorad R, Genestie C, Bernichtein S, Badachi Y, Janaud G, Akakpo JP, Bachelot A, Kuttenn F, Goffin V, Touraine P: Characterization of two constitutively active prolactin receptor variants in a cohort of 95 women with multiple breast fibroadenomas. J Clin Endocrinol Metab. 2010, 95: 271-279. 10.1210/jc.2009-1494.CrossRef Courtillot C, Chakhtoura Z, Bogorad R, Genestie C, Bernichtein S, Badachi Y, Janaud G, Akakpo JP, Bachelot A, Kuttenn F, Goffin V, Touraine P: Characterization of two constitutively active prolactin receptor variants in a cohort of 95 women with multiple breast fibroadenomas. J Clin Endocrinol Metab. 2010, 95: 271-279. 10.1210/jc.2009-1494.CrossRef
19.
go back to reference Lee SA, Haiman CA, Burtt NP, Pooler LC, Cheng I, Kolonel LN, Pike MC, Altshuler D, Hirschhorn JN, Henderson BE, Stram DO: A comprehensive analysis of common genetic variation in prolactin (PRL) and PRL receptor (PRLR) genes in relation to plasma prolactin levels and breast cancer risk: the multiethnic cohort. BMC Med Genet. 2007, 8: 72-CrossRef Lee SA, Haiman CA, Burtt NP, Pooler LC, Cheng I, Kolonel LN, Pike MC, Altshuler D, Hirschhorn JN, Henderson BE, Stram DO: A comprehensive analysis of common genetic variation in prolactin (PRL) and PRL receptor (PRLR) genes in relation to plasma prolactin levels and breast cancer risk: the multiethnic cohort. BMC Med Genet. 2007, 8: 72-CrossRef
20.
go back to reference Vaclavicek A, Hemminki K, Bartram CR, Wagner K, Wappenschmidt B, Meindl A, Schmutzler RK, Klaes R, Untch M, Burwinkel B, Forsti A: Association of prolactin and its receptor gene regions with familial breast cancer. J Clin Endocrinol Metab. 2006, 91: 1513-1519. 10.1210/jc.2005-1899.CrossRef Vaclavicek A, Hemminki K, Bartram CR, Wagner K, Wappenschmidt B, Meindl A, Schmutzler RK, Klaes R, Untch M, Burwinkel B, Forsti A: Association of prolactin and its receptor gene regions with familial breast cancer. J Clin Endocrinol Metab. 2006, 91: 1513-1519. 10.1210/jc.2005-1899.CrossRef
21.
go back to reference Garcia-Closas M, Brinton LA, Lissowska J, Chatterjee N, Peplonska B, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W, Blair A, Kalaylioglu Z, Rymkiewicz G, Mazepa-Sikora D, Kordek R, Lukaszek S, Sherman ME: Established breast cancer risk factors by clinically important tumour characteristics. Br J Cancer. 2006, 95: 123-129. 10.1038/sj.bjc.6603207.CrossRef Garcia-Closas M, Brinton LA, Lissowska J, Chatterjee N, Peplonska B, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W, Blair A, Kalaylioglu Z, Rymkiewicz G, Mazepa-Sikora D, Kordek R, Lukaszek S, Sherman ME: Established breast cancer risk factors by clinically important tumour characteristics. Br J Cancer. 2006, 95: 123-129. 10.1038/sj.bjc.6603207.CrossRef
22.
go back to reference Wang J, Lin M, Crenshaw A, Hutchinson A, Hicks B, Yeager M, Berndt S, Huang WY, Hayes RB, Chanock SJ, Jones RC, Ramakrishnan R: High-throughput single nucleotide polymorphism genotyping using nanofluidic Dynamic Arrays. BMC Genomics. 2009, 10: 561-10.1186/1471-2164-10-561.CrossRef Wang J, Lin M, Crenshaw A, Hutchinson A, Hicks B, Yeager M, Berndt S, Huang WY, Hayes RB, Chanock SJ, Jones RC, Ramakrishnan R: High-throughput single nucleotide polymorphism genotyping using nanofluidic Dynamic Arrays. BMC Genomics. 2009, 10: 561-10.1186/1471-2164-10-561.CrossRef
23.
go back to reference Schaid DJ: Evaluating associations of haplotypes with traits. Genet Epidemiol. 2004, 27: 348-364. 10.1002/gepi.20037.CrossRef Schaid DJ: Evaluating associations of haplotypes with traits. Genet Epidemiol. 2004, 27: 348-364. 10.1002/gepi.20037.CrossRef
24.
go back to reference Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA: Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet. 2002, 70: 425-434. 10.1086/338688.CrossRef Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA: Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet. 2002, 70: 425-434. 10.1086/338688.CrossRef
25.
go back to reference Fujimoto VY, Clifton DK, Cohen NL, Soules MR: Variability of serum prolactin and progesterone levels in normal women: the relevance of single hormone measurements in the clinical setting. Obstet Gynecol. 1990, 76: 71-78.PubMed Fujimoto VY, Clifton DK, Cohen NL, Soules MR: Variability of serum prolactin and progesterone levels in normal women: the relevance of single hormone measurements in the clinical setting. Obstet Gynecol. 1990, 76: 71-78.PubMed
26.
go back to reference Kotsopoulos J, Eliassen AH, Missmer SA, Hankinson SE, Tworoger SS: Relationship between caffeine intake and plasma sex hormone concentrations in premenopausal and postmenopausal women. Cancer. 2009, 115: 2765-2774. 10.1002/cncr.24328.CrossRef Kotsopoulos J, Eliassen AH, Missmer SA, Hankinson SE, Tworoger SS: Relationship between caffeine intake and plasma sex hormone concentrations in premenopausal and postmenopausal women. Cancer. 2009, 115: 2765-2774. 10.1002/cncr.24328.CrossRef
27.
go back to reference Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Stat Methodol. 1995, 57: 289-300. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Stat Methodol. 1995, 57: 289-300.
28.
go back to reference Canbay E, Degerli N, Gulluoglu BM, Kaya H, Sen M, Bardakci F: Could prolactin receptor gene polymorphism play a role in pathogenesis of breast carcinoma?. Curr Med Res Opin. 2004, 20: 533-540. 10.1185/030079904125003232.CrossRef Canbay E, Degerli N, Gulluoglu BM, Kaya H, Sen M, Bardakci F: Could prolactin receptor gene polymorphism play a role in pathogenesis of breast carcinoma?. Curr Med Res Opin. 2004, 20: 533-540. 10.1185/030079904125003232.CrossRef
29.
go back to reference McCormack VA, Dowsett M, Folkerd E, Johnson N, Palles C, Coupland B, Holly JM, Vinnicombe SJ, Perry NM, dos Santos Silva I: Sex steroids, growth factors and mammographic density: a cross-sectional study of UK postmenopausal Caucasian and Afro-Caribbean women. Breast Cancer Res. 2009, 11: R38-10.1186/bcr2325.CrossRef McCormack VA, Dowsett M, Folkerd E, Johnson N, Palles C, Coupland B, Holly JM, Vinnicombe SJ, Perry NM, dos Santos Silva I: Sex steroids, growth factors and mammographic density: a cross-sectional study of UK postmenopausal Caucasian and Afro-Caribbean women. Breast Cancer Res. 2009, 11: R38-10.1186/bcr2325.CrossRef
30.
go back to reference Duan R, Ginsburg E, Vonderhaar BK: Estrogen stimulates transcription from the human prolactin distal promoter through AP1 and estrogen responsive elements in T47D human breast cancer cells. Mol Cell Endocrinol. 2008, 281: 9-18. 10.1016/j.mce.2007.10.004.CrossRef Duan R, Ginsburg E, Vonderhaar BK: Estrogen stimulates transcription from the human prolactin distal promoter through AP1 and estrogen responsive elements in T47D human breast cancer cells. Mol Cell Endocrinol. 2008, 281: 9-18. 10.1016/j.mce.2007.10.004.CrossRef
Metadata
Title
Genetic variation in PRL and PRLR, and relationships with serum prolactin levels and breast cancer risk: results from a population-based case-control study in Poland
Authors
Sarah J Nyante
Jessica M Faupel-Badger
Mark E Sherman
Ruth M Pfeiffer
Mia M Gaudet
Roni T Falk
Abegail A Andaya
Jolanta Lissowska
Louise A Brinton
Beata Peplonska
Barbara K Vonderhaar
Stephen Chanock
Montserrat Garcia-Closas
Jonine D Figueroa
Publication date
01-04-2011
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 2/2011
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2864

Other articles of this Issue 2/2011

Breast Cancer Research 2/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine